Coordinatore | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
Nazionalità Coordinatore | France [FR] |
Sito del progetto | http://www.e-rare.eu/ |
Totale costo | 2˙920˙521 € |
EC contributo | 1˙999˙680 € |
Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
Code Call | FP7-ERANET-2010-RTD |
Funding Scheme | CSA-CA |
Anno di inizio | 2010 |
Periodo (anno-mese-giorno) | 2010-10-01 - 2014-11-30 |
# | ||||
---|---|---|---|---|
1 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | coordinator | 548˙938.50 |
2 |
DEUTSCHES ZENTRUM FUER LUFT - UND RAUMFAHRT EV
Organization address
address: Linder Hoehe contact info |
DE (KOELN) | participant | 316˙767.90 |
3 |
INSTITUTO DE SALUD CARLOS III
Organization address
address: CALLE SINESIO DELGADO 4-6 contact info |
ES (MADRID) | participant | 192˙658.00 |
4 |
AGENCE NATIONALE DE LA RECHERCHE
Organization address
address: 50 avenue Daumesnil contact info |
FR (PARIS) | participant | 190˙222.30 |
5 |
ISTITUTO SUPERIORE DI SANITA
Organization address
address: Viale Regina Elena 299 contact info |
IT (ROMA) | participant | 187˙851.50 |
6 |
FONDS NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Organization address
address: Rue d'Egmont 5 contact info |
BE (BRUXELLES) | participant | 114˙153.90 |
7 |
MINISTRY OF HEALTH
Organization address
address: 2 Ben Tabai Street contact info |
IL (JERUSALEM) | participant | 81˙962.00 |
8 |
THE NETHERLANDS ORGANISATION FOR HEALTH RESEARCH AND DEVELOPMENT
Organization address
address: Laan Van Nieuw Oost Indie 334 contact info |
NL (DEN HAAG) | participant | 78˙564.50 |
9 |
KENTROU ELEGHOU & PROLIPSIS NOSIMATON
Organization address
address: AGRAFON 3-5 contact info |
EL (MAROUSI) | participant | 75˙907.95 |
10 |
FUNDACAO PARA A CIENCIA E A TECNOLOGIA
Organization address
address: AVENIDA D CARLOS I 126 contact info |
PT (LISBOA) | participant | 50˙290.00 |
11 |
Nome Ente NON disponibile
Organization address
address: SENSENGASSE 1 contact info |
AT (WIEN) | participant | 34˙055.88 |
12 |
GENIKI GRAMMATIA EREVNAS KAI TECHNOLOGIAS
Organization address
address: Mesogeion Avenue 14-18 contact info |
EL (ATHENS) | participant | 32˙100.00 |
13 |
TURKIYE BILIMSEL VE TEKNOLOJIK ARASTIRMA KURUMU
Organization address
address: Ataturk Bulvari 221 contact info |
TR (ANKARA) | participant | 31˙598.00 |
14 |
PECSI TUDOMANYEGYETEM - UNIVERSITY OF PECS
Organization address
address: VASVARI PAL UTCA 4 contact info |
HU (PECS) | participant | 30˙943.50 |
15 |
Unitatea Executiva pentru Finantarea Invatamantului Superior, a Cercetarii, Dezvoltarii si Inovarii
Organization address
address: Mendeleev Street 21-25 contact info |
RO (Bucharest) | participant | 20˙826.48 |
16 |
MINISTERIO DA SAUDE - REPUBLICA PORTUGUESA
Organization address
city: LISBOA contact info |
PT (LISBOA) | participant | 12˙840.00 |
17 |
BUNDESMINISTERIUM FUER BILDUNG UND FORSCHUNG
Organization address
address: Heinemannstrasse 2 contact info |
DE (BONN) | participant | 0.00 |
18 |
INSTITUTO NACIONAL DE SAUDE DR. RICARDO JORGE
Organization address
address: AVENIDA PADRE CRUZ . contact info |
PT (LISBOA) | participant | 0.00 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
'Rare diseases represent an important public-health issue, affecting 26-30 million persons across Europe, and a major challenge for research. The fragmentation of resources and knowledge for the 6000-8000 rare diseases and the lack of treatment for the majority of them necessitate a coordinated European approach to unravel the underlying molecular defects and pathophysiological mechanisms. The low number of affected patients requires transnational collaboration with multidisciplinary approaches to map prevalences, build patient registries, identify biomarkers, develop new diagnostics and finally perform clinical studies for the development of treatments. The successful linking of research funding organisations in E-Rare-1 and the subsequent exemplary joint funding activities have attested the need of, and the acknowledgment from, the research community for transnational funding of collaborative, multidisciplinary and ambitious projects on rare diseases. It has leveraged funding for rare disease research in countries without specific programmes for rare diseases and thus enabled the participation of researchers in these countries to transnational projects. The E-Rare-2 project aims at deepening and extending the cooperation among the E-Rare-1 and the five new partners by systematic exchange of information, yearly launching of joint calls, thorough assessment of the funding mechanisms and results of the funded research projects and, finally, strategic activities aiming at a sustainable development and extension of the network. Special attention will be given to the outreach and knowledge exchange with new member states, countries outside of Europe and key stakeholders/initiatives important for rare diseases. E-Rare-2 activities will thus further contribute to reducing fragmentation of research and resources through the enhanced coordination and transnational funding of excellent research on rare diseases, thereby shaping the European Research Area for rare diseases.'
Research efforts need to be coordinated and available funds pooled to find out how rare diseases arise and affect humans. Scientists can build patient registries, find out how prevalent each disease is and find biological molecules that confirm the presence of the disease. This will allow for better diagnostics and treatments to be tested in clinical studies.
The EU-funded ?ERA-NET on rare diseases? (E-RARE-2) project is building on the work of its predecessor E-RARE-1 to strengthen rare disease research and funding networks. In particular, this second phase will focus on including New Member States (NMS), non-European countries and other important stakeholders and initiatives.
In 2011, the first call for joint, transnational research proposals resulted in funding of EUR 8.78 million for over 60 research groups from 13 consortia. The successful research bids covered a range of diseases and potential therapies, including stem cells, gene therapy and customised animal models.
The 2012 call is still open and is aimed at young, independent scientists. E-RARE-2 has identified research areas that need special attention, and this call addresses those topics specifically.
These research calls have demonstrated that scientists are keen to work together on rare conditions. To further strengthen these networks and to create awareness, E-RARE-2 uses various communication tools and it is also developing an online research portal. This portal will eventually become a forum for information exchange and a search engine to find collaborators.
With these successes to drive it forward, E-RARE-2 will continue to diversify its activities and increase funding commitment from new and existing funders.
"European multicenter network to evaluate pharmacokinetics, safety and efficacy of Meropenem in neonatal sepsis and meningitis"
Read More"Efficacy and safety of MRI-based thrombolysis in wake-up stroke: a randomised, double-blind, placebo-controlled trial"
Read MoreNew approaches in the development of Hypoallergenic implant material in Orthopaedics: steps to personalised medicine
Read More